Vasogen To Present at Rodman and Renshaw Techvest 6th Annual Healthcare Conference

Toronto, Ontario - October 21, 2004

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today announced that its President and Chief Executive Officer, David Elsley, will present a Company overview at the Rodman and Renshaw Techvest 6th Annual Healthcare Conference at the Waldorf Astoria in New York City at 10:25 a.m. (ET) on Wednesday, October 27, 2004.

A webcast of the presentation can be accessed through Vasogen's website at www.vasogen.com. An archived replay will be available following the presentation.

Vasogen is a leader in the research and commercial development of immune modulation therapies targeting the chronic inflammation underlying cardiovascular disorders. Vasogen's lead product, Celacade™ (immune modulation therapy) is currently in pivotal phase III clinical trials for the treatment of chronic heart failure and peripheral arterial disease. The Company's 2,000-patient ACCLAIM trial, being conducted at cardiac centers throughout North America and Europe, is investigating the impact of Celacade™ on reducing the risk of mortality and morbidity in advanced chronic heart failure patients. Vasogen's 500-patient SIMPADICO trial, being conducted at medical centers throughout North America, is designed to further investigate the impact of Celacade™ on reducing the debilitating symptoms associated with peripheral arterial disease. Celacade™ is designed to target chronic inflammation by activating the immune system's physiological anti-inflammatory response to apoptotic cells. Vasogen is also developing a new class of drugs, designed to interact with immune cells leading to the modulation of cytokines - potent chemical messengers that regulate and control inflammation. VP025, the lead candidate from this new class of drugs, is in preclinical development for the treatment of neurodegenerative disorders including Parkinson's and Alzheimer's disease.

---